Shares of Natco Pharma rallied 9 per cent to Rs 920 on the BSE in Tuesday’s intra-day trade after the company launched its first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the US market. Natco, along with marketing partner Teva, has launched these strengths of lenalidomide.

• Elecon Engineering Hits Rs 440 High on Rs 1,635 Cr Order Book
• Balkrishna Industries Signs Pirelli Deal for Car Tyres
• KSH International Shares Rise 3% on Power Grid Nod
• Apollo Micro Systems Arm Opens 9,000-Tonne Explosives Plant
• Adani Energy Solutions Q2 Profit Surges 148%

In the above strengths of lenalidomide, capsules are prescribed in adults to treat multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment, Natco Pharma said in an exchange filing.